Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PALI | Palisade Bio, Inc.

Index	-	P/E	-	EPS (ttm)	-7.23	Insider Own	0.30%	Shs Outstand	9.20M	Perf Week	-6.65%
Market Cap	5.40M	Forward P/E	-	EPS next Y	-0.87	Insider Trans	111.11%	Shs Float	8.50M	Perf Month	-5.66%
Income	-13.40M	PEG	-	EPS next Q	-0.34	Inst Own	11.00%	Short Float / Ratio	2.04% / 0.06	Perf Quarter	-66.08%
Sales	0.30M	P/S	18.00	EPS this Y	88.70%	Inst Trans	17.03%	Short Interest	0.17M	Perf Half Y	-66.28%
Book/sh	2.46	P/B	0.24	EPS next Y	45.30%	ROA	-82.00%	Target Price	16.00	Perf Year	-90.72%
Cash/sh	1.76	P/C	0.33	EPS next 5Y	-	ROE	-98.80%	52W Range	0.55 - 8.54	Perf YTD	-88.85%
Dividend	-	P/FCF	-	EPS past 5Y	70.50%	ROI	-	52W High	-93.21%	Beta	1.74
Dividend %	-	Quick Ratio	7.50	Sales past 5Y	-	Gross Margin	-	52W Low	5.36%	ATR	0.13
Employees	12	Current Ratio	7.50	Sales Q/Q	-	Oper. Margin	-	RSI (14)	39.13	Volatility	6.32% 12.30%
Optionable	No	Debt/Eq	0.03	EPS Q/Q	90.80%	Profit Margin	-	Rel Volume	0.07	Prev Close	0.59
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 11 BMO	Payout	-	Avg Volume	2.99M	Price	0.58
Recom	2.00	SMA20	-16.91%	SMA50	-53.68%	SMA200	-69.30%	Volume	203,988	Change	-1.69%

Sep-14-23 07:13PM	Insider Buying: John Finley Acquires 15,000 Shares of Palisade Bio Inc (GuruFocus.com)
Sep-11-23 04:01PM	Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules (GlobeNewswire)
08:35AM	Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer (GlobeNewswire)
Sep-07-23 08:30AM	Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules (GlobeNewswire) -45.85%
Sep-06-23 08:45AM	Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease (GlobeNewswire) +108.79%
08:05AM	Loading…
Aug-11-23 08:05AM	Palisade Bio Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-09-23 08:05AM	Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions (GlobeNewswire) -62.70%
Jul-05-23 08:45AM	Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study (GlobeNewswire)
Jun-22-23 08:30AM	PALISADES ANNOUNCES NEW FOUND MAKES NEW HIGH-GRADE, AT SURFACE DISCOVERY AT JACKPOT ZONE AT QUEENSWAY PROJECT (CNW Group)
Jun-14-23 08:45AM	Palisade Bio Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (GlobeNewswire)
Jun-01-23 08:45AM	Palisade Bio Promotes J.D. Finley to Chief Executive Officer (GlobeNewswire) +9.09%
May-24-23 08:45AM	Palisade Bios LB1148 Two Ongoing Clinical Trials Expecting Topline Data Readouts (GlobeNewswire) -7.64%
May-17-23 08:30AM	PALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT KEATS WEST (CNW Group)
May-12-23 08:05AM	Palisade Bio Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-11-23 09:05AM	Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study (GlobeNewswire)
09:00AM	Loading…
Apr-06-23 09:00AM	Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148 (GlobeNewswire)
Apr-05-23 08:35AM	Palisade Bio Announces Enrollment of First Patient in Newsoara Phase 3 Clinical Trial Evaluating LB1148 (GlobeNewswire) +7.39%
Apr-04-23 08:30AM	PALISADES ANNOUNCES NEW FOUND GOLD INTERCEPTS AT ICEBERG (CNW Group) -10.18%
Apr-03-23 08:30AM	Palisade Bio Announces $6 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules (GlobeNewswire) -35.80%
Mar-23-23 08:05AM	Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-15-23 08:30AM	PALISADES ANNOUNCES NEW FOUND'S INCREASED WEIGHTING BY GDXJ (CNW Group) -6.60%
Mar-01-23 09:05AM	Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent (GlobeNewswire)
Feb-08-23 08:35AM	Palisade Bio Promotes Robert McRae to Chief Operating Officer (GlobeNewswire)
Jan-11-23 01:00PM	JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th (ACCESSWIRE)
Jan-10-23 08:35AM	Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million (GlobeNewswire)
Jan-09-23 08:45AM	Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event (GlobeNewswire)
Jan-04-23 05:15PM	Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules (GlobeNewswire) +6.02%
Dec-30-22 08:45AM	Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules (GlobeNewswire) +61.49%
Dec-16-22 08:05AM	Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions (GlobeNewswire)
Dec-07-22 08:35AM	Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million (GlobeNewswire) -6.81%
02:44PM	Loading…
Dec-01-22 02:44PM	Palisade Bio Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Nov-22-22 08:35AM	Palisade Bio is Granted Fast Track Designation from the U.S. Food and Drug Administration for LB1148 for Accelerated Return of Bowel Function following GI Surgery (GlobeNewswire) +81.90%
Nov-18-22 08:05AM	Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer (GlobeNewswire) -7.89%
Nov-17-22 08:30AM	Palisade Bio Releases In-Depth Explanation of Scientific Approach of Lead Product Candidate LB1148 Through Animated Video (GlobeNewswire) -5.67%
Nov-15-22 11:15AM	Palisade Bio Announces Reverse Stock Split (GlobeNewswire) -18.56%
Nov-14-22 08:45AM	Palisade Bio Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Oct-11-22 09:25AM	Palisade Bio Announces Executive Leadership Transition (GlobeNewswire) -12.78%
Sep-29-22 08:35AM	Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022 (GlobeNewswire) -6.28%
Sep-23-22 04:30PM	Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.61%
Sep-21-22 09:23AM	Palisade Bio to Present at the Ladenburg Thalmann 2022 Healthcare Conference (GlobeNewswire)
Sep-15-22 08:30AM	Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on Advancement of Lead Clinical Program, LB1148 (GlobeNewswire) -9.15%
Sep-13-22 09:05AM	Palisade Bio to Present at the Virtual Investor Innovations in Intestinal Health - Launching a Pivotal Phase 3 Study for Return of Postoperative Bowel Function Event (GlobeNewswire) +18.33%
Aug-17-22 08:35AM	Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function (GlobeNewswire) -21.41%
Aug-16-22 04:05PM	Palisade Bio Announces Closing of $13.8 Million Upsized Underwritten Public Offering and Full Exercise of Over-Allotment Option (GlobeNewswire) -10.99%
Aug-15-22 09:00AM	Palisade Bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-12-22 08:30AM	Palisade Bio Announces Pricing of $12 Million Upsized Underwritten Public Offering (GlobeNewswire) -28.81%
Aug-01-22 08:05AM	Palisade Bio Launches New Corporate Website and Reiterates Commitment to Develop Therapeutics that Protect Intestinal Barrier Health (GlobeNewswire)
Jul-27-22 08:05AM	Palisade Bio Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function (GlobeNewswire)
Jun-29-22 08:30AM	Palisade Bio Initiates Phase 3 Study of LB1148 in Lead Indication for Postoperative Return of Bowel Function (GlobeNewswire)
Jun-07-22 08:30AM	Palisade Bio to Present at the 2022 BIO International Convention (GlobeNewswire)
May-13-22 09:00AM	Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +7.17%
May-10-22 05:00PM	Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires (GlobeNewswire) +11.03%
May-06-22 08:30AM	Palisade Bio Announces $2.0 Million Registered Direct Offering (GlobeNewswire) -27.61%
May-05-22 08:30AM	Palisade Bio and Newsoara Receive NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery (GlobeNewswire)
May-02-22 08:35AM	Palisade Bio Provides Business Outlook and Highlights Expected Near-Term Pipeline Advancements (GlobeNewswire) -5.76%
Apr-29-22 08:05AM	Palisade Bio to Participate in the Virtual Investor Management and KOL Roundtable Event (GlobeNewswire)
Mar-30-22 03:47PM	Companies Like Palisade Bio (NASDAQ:PALI) Could Be Quite Risky (Simply Wall St.)
Mar-24-22 08:30AM	Palisade Bio (Nasdaq: PALI) to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group and Hosted by M-Vest (GlobeNewswire)
Mar-22-22 08:30AM	Palisade Bio (Nasdaq: PALI) Receives FDA Study May Proceed Letter for Pivotal Phase 3 Clinical Trial Evaluating LB1148 to Accelerate the Return of Bowel Function Following Abdominal Surgery (GlobeNewswire) +30.43%
Mar-18-22 08:30AM	Palisade Bio (Nasdaq: PALI) Reports Year End 2021 Financial Results and Corporate Update (GlobeNewswire) -11.56%
Mar-16-22 08:00AM	Palisade Bio (Nasdaq: PALI) Announces Analysis Demonstrating LB1148 Reduced the Extent and Severity of Post-Surgical Intraabdominal Adhesions by 93% (GlobeNewswire) -16.10%
Mar-14-22 09:15AM	Preventing Post-Surgical Abdominal Adhesions: Virtual Presentation on Palisade Bio's LB1148 Clinical Data; To Be Hosted & Moderated by Stonegate Capital Partners (Newsfile) -6.97%
Mar-09-22 08:30AM	Palisade Bio (Nasdaq: PALI) to Present New Clinical Data of LB1148 for Preventing Adhesions in Conjunction with Next Big Thing Session at Society of American Gastrointestinal and Endoscopic Surgeons 2022 Annual Meeting (GlobeNewswire) +10.45%
Feb-18-22 08:30AM	Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference (GlobeNewswire)
Feb-15-22 08:30AM	Palisade Bio (NASDAQ: PALI) Adds Pharmaceutical Industry Executive Robert McRae to Leadership Team (GlobeNewswire)
Feb-08-22 08:00AM	Palisade Bio (Nasdaq: PALI) to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting (GlobeNewswire) +8.33%
Dec-29-21 08:30AM	Palisade Bio to Present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase (GlobeNewswire)
Dec-08-21 08:00AM	Palisade Bio Granted New U.S. Patent Covering Protease Inhibitor LB1148 for Treating Adhesions and Postoperative Ileus (GlobeNewswire) +5.26%
Nov-30-21 08:00AM	Palisade Bio Announces the European Patent Office to Grant a Patent for its Lead Drug Candidate LB1148, Providing Protection Through 2035 (GlobeNewswire)
Nov-23-21 08:00AM	Palisade Bio Announces Inducement Awards Under Inducement Plan for Key New Hires, Including Nick McCoy, Vice President of Clinical Operations (GlobeNewswire)
Nov-15-21 07:00AM	Palisade Bio Reports Third Quarter Financial Results (GlobeNewswire)
Oct-22-21 08:00AM	Palisade Bio, Inc. Announces Sale of Seneca Asset NSI-189 for the Treatment of Central Nervous System Disorders (GlobeNewswire) -6.79%
Sep-09-21 08:30AM	Palisade Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference (GlobeNewswire) +8.21%
Aug-24-21 08:15AM	Palisade Bio Reports Second Quarter Financial Results and Provides Business Update (GlobeNewswire) -5.80%
Aug-20-21 09:25AM	Palisade Bio Announces $5.2M Investment by the Yuma Regional Medical Center (GlobeNewswire)
Jul-29-21 08:15AM	Palisade Bio and Newsoara Announce Positive Topline Efficacy Results from Phase 2 Study of LB1148 Demonstrating Accelerated Return of Bowel Function After Gastrointestinal Surgery (GlobeNewswire) -9.20%
Jul-13-21 08:00AM	Palisade Bio Enters into Worldwide In-Licensing Agreement with University of California for Technology to Support Target Identification, Drug Discovery, and Clinical Development (GlobeNewswire)
Jun-15-21 08:15AM	Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide Preparation for Late-Stage Clinical Trials of LB1148 in Accelerating Postoperative Return of Bowel Function and Reduction of Post-Surgical Adhesions (GlobeNewswire)
Jun-07-21 05:06PM	Neuralstem Worker Tipped Partner to Trial Results, SEC Says (Bloomberg) +11.11%
May-13-21 07:00AM	Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery (GlobeNewswire) -12.38%
May-07-21 09:07AM	Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China (GlobeNewswire)
May-04-21 08:00AM	Palisade Bio Hosting Key Opinion Leader Webinar on LB1148, an Oral Serine Protease Inhibitor for Postoperative GI Dysfunction (GlobeNewswire) -7.00%

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Trenschel Robert J.	Director	Sep 14	Sale	0.64	300	192	0	Sep 15 05:15 PM
Finley John David	CEO, CFO, Director	Sep 13	Buy	0.66	15,000	9,825	28,394	Sep 14 05:00 PM
Finley John David	CEO, CFO, Director	Sep 11	Option Exercise	0.00	5,558	0	15,186	Sep 13 04:55 PM
Finley John David	CEO, CFO, Director	Aug 06	Option Exercise	0.00	3,475	0	11,057	Aug 14 06:33 PM
Finley John David	CEO, CFO, Director	Jul 03	Option Exercise	0.00	1,309	0	7,582	Jul 06 06:27 PM
Finley John David	CEO, CFO, Director	Jun 12	Option Exercise	0.00	3,475	0	7,323	Jun 14 06:23 PM
McRae Robert Curtis	Chief Operating Officer	Apr 03	Option Exercise	0.00	655	0	895	Apr 05 06:52 PM
Finley John David	CEO, CFO, Director	Apr 03	Option Exercise	0.00	1,309	0	4,283	Apr 05 06:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PALI | Palisade Bio, Inc.

Upgrade your FINVIZ experience